Jasper Therapeutics Inc Ordinary Shares JSPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
-
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
-
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $0.53
- Day Range
- $0.50–0.55
- 52-Week Range
- $0.32–2.69
- Bid/Ask
- $0.50 / $0.50
- Shares Outstanding
- 33.27M
- Market Cap
- $16.49M
- Volume/Avg
- 92,152 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
Valuation
|
Metric
|
JSPR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.85 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
JSPR
Financial Strength
|
Metric
|
JSPR
|
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 1.47 |
Interest Coverage | — |
Quick Ratio
JSPR
Profitability
|
Metric
|
JSPR
|
|---|---|
Return on Assets (Normalized) | −143.74% |
Return on Equity (Normalized) | −563.71% |
Return on Invested Capital (Normalized) | −504.16% |
Return on Assets
JSPR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Y#$l!dW | LOCK|%#%L | $129B | |||
| Moderna Inc
MRNA
| LOCK|%Zl<sd | LOCK|&g | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|pGG?d> | LOCK|?h#$P | $82B | |||
| argenx SE ADR
ARGX
| LOCK|K$yB?h% | LOCK|@<@ | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?@@S>x | LOCK|C? | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?mj$Y% | LOCK|@$nx | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!?bq?rf | LOCK|N$zD | $27B | |||
| Incyte Corp
INCY
| LOCK|l#CGgs | LOCK|RY | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!%?N^z | LOCK|#k | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!^K@@>@ | LOCK|$yF | $14B |
United States